|
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to present our institutional observations regarding to the association of ERCC1 and overall survival (OS) of the lung adenocarcinoma patients who received chemotherapy based on platinum.
|
31521181 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma.
|
30584903 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.
|
28260069 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
|
28128193 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study provides a solid rationale for the stratification of lung adenocarcinoma patients according to the functional ERCC1- and mutational TP53 status, where functionally ERCC1-incompetent patients could benefit from sequential cisplatin and etoposide chemotherapy.
|
27514406 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry demonstrated that the percentage of pleural fluid samples from patients with lung adenocarcinoma expressing ERCC1, TYMS, RRM1 and TUBB3 was 37, 36.2, 82.7 and 69.8%, respectively.
|
25573098 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.
|
23581229 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ERCC1 protein-level expression was predicted by activated p38 MAPK in lung adenocarcinoma tissues.
|
22415779 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
CTD_human |
Using suppression subtractive hybridization and a microarray analysis to identify drug resistance-associated DNA repair-related genes, we found that the mRNA levels of ERCC1, MSH-3, MSH-6 and XPC were significantly increased in LADC patients.
|
21327329 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
The T/T homozygote in ERCC1 (Asn118Asn) was correlated with a strong statistically significant increased risk of developing lung cancer (adjusted OR=2.44; 95% CI=1.13-5.28; P=0.023), especially lung adenocarcinoma (adjusted OR=3.18) and small cell lung cancer (adjusted OR=6.08).
|
20354815 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate the association between the ERCC2 751, 312 and ERCC1 118 polymorphisms and the risk of lung adenocarcinoma in Chinese non-smoking females.
|
20003391 |
2009 |
|
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increasing numbers of either ERCC1 118 or XRCC1 399 variant alleles were associated with shorter survival of non-smoking female lung adenocarcinoma patients (Log-rank P < 0.001).
|
20003463 |
2009 |